Form 4: Corcept Therapeutics Director, Kimberly Park, Acquires 30,000 Stock Options

Director Kimberly Park acquired 30,000 stock options in Corcept Therapeutics on May 17, 2024, exercisable over a one-year period.

Summary

• On May 17, 2024, Kimberly Park, a director of Corcept Therapeutics, acquired 30,000 stock options.
• The exercise price of these options is $28.09.
• The options become exercisable ratably in equal monthly installments over a one-year period, starting May 17, 2024.
• The options expire on May 16, 2034.
• Following the transaction, Kimberly Park directly owns 30,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option acquisition by a director. While insider buying can be seen as positive, it's a standard part of executive compensation.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders (officers, directors, or those holding more than 10% of the company's shares) buy or sell the company's securities. These filings provide transparency into insider transactions and are closely watched by investors for signals about a company's prospects.

Stakeholder Impact

• Shareholders may view the acquisition of stock options by a director as a sign of confidence in the company's future.

Key Dates